Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Inclusion Criteria:

Unresectable and/or metastatic HLA-G-positive solid tumors, for which standard therapy does not exist, or has proven to be ineffective or intolerable

The following tumor histologies will be permitted:

1. Part I and Part II: renal cell carcinoma (clear cell, papillary, chromophobe or unclassified), non-small cell lung cancer (squamous or non-squamous), pancreatic adenocarcinoma, colorectal cancer, epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer of the following subtype: serous high-grade carcinoma
2. Part III: renal cell carcinoma with a clear-cell component; must have IMDC poor or intermediate risk disease and must have received no more than 3 prior systemic therapies in the advanced or metastatic setting (prior treatment must include an immune checkpoint inhibitor)
3. Confirmed HLA-G tumor expression. Participants without archival tumor tissue available for testing must have a lesion amenable to biopsy.

Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

1. For Part I only: non-measurable evaluable disease is acceptable.
2. For participants in Part I with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: participants without a measurable lesion must have evaluable disease and/or have CA-125 greater than 2 times the upper limit of normal (ULN) within 2 weeks prior to first dose of study drug.
3. Life expectancy of at least 12 weeks
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
5. Adequate hematological, liver, renal and pulmonary function
6. Willingness to abide by protocol defined contraceptive requirements for the duration of the study.

Exclusion Criteria:

1. History or clinical evidence of Central Nervous System (CNS) metastases unless protocol specified criteria are met
2. Leptomeningeal metastases
3. Rapid disease progression including lesions that are a threat to vital organs or non-irradiated lesions 2cm or larger at critical sites where tumor swelling may pose a risk to critical anatomical structures
4. Participants with another invasive malignancy in the last 2 years unless protocol specified criteria are met
5. Uncontrolled hypertension
6. Active interstitial lung disease (ILD), pneumonitis or a history of ILD/pneumonitis requiring treatment with steroids, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan
7. Participants with central cavitation or tumor(s) shown to be invading or abutting major blood vessels by imaging or the Investigator determines the tumor(s) is likely to invade major blood vessels and cause fatal bleeding
8. Participants with pulmonary military metastatic pattern or pulmonary lymphangitic carcinomatosis
9. History of pulmonary embolism within 3 months prior to study entry
10. Significant cardiovascular disease
11. Presence of active or uncontrolled infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to initiation of study treatment.
12. Known hepatitis B or C (actively replicating) based on protocol specified criteria
13. Known Human Immunodeficiency Virus (HIV) positivity
14. Presence of an indwelling line or drain
15. Active auto-immune disease that has required systemic therapy within the past 2 years unless protocol specified exceptions are met
16. Major surgery within 28 days prior to first study treatment
17. Last treatment with anti-cancer therapy or any investigational drug 28 days or less prior to the first study treatment
18. Last dose of immunostimulating or immunosuppressive therapy 28 days or less prior to the first study treatment
19. Regular dose of corticosteroids that exceeds prednisone 10 mg/day or equivalent within 28 days prior to first study treatment
20. Prior treatment with T cell engaging or adoptive cell therapy
21. Administration of a live, attenuated vaccine 28 days or less prior to first study treatment
22. Contraindication or known hypersensitivity to any of the components of RO7515629 or tocilizumab or dexamethasone